Aspire Biopharma Holdings (ASBP) Total Liabilities (2021 - 2026)

Aspire Biopharma Holdings (ASBP) has 6 years of Total Liabilities data on file, last reported at $3.2 million in Q1 2026.

• On a quarterly basis, Total Liabilities fell 67.25% year-over-year to $3.2 million in Q1 2026; TTM through Mar 2026 was $3.2 million, a 67.25% decrease from a year earlier, with the FY2025 full-year figure at $7.7 million, up 355.46% from the prior year.
• Total Liabilities for Q1 2026 stood at $3.2 million, down from $7.7 million in the prior quarter.
• Over the last five years, Total Liabilities for ASBP reached as high as $13.9 million in Q3 2025 and fell as low as $284356.0 in Q2 2023.
• Historically, Total Liabilities has averaged $7.0 million across 5 years, with a median of $8.8 million in 2025.
• Across the five-year window, Total Liabilities soared 3684.81% in 2022 and tumbled 97.41% in 2023, its largest moves.
• Year by year, Total Liabilities stood at $11.1 million in 2022, then slumped by 96.37% to $403328.0 in 2023, then soared by 318.54% to $1.7 million in 2024, then surged by 355.46% to $7.7 million in 2025, then tumbled by 57.75% to $3.2 million in 2026.
• Per Business Quant data, the three most recent Total Liabilities figures were $3.2 million in Q1 2026, $7.7 million in Q4 2025, and $13.9 million in Q3 2025.